Alpha Tau Medical shares hit 52-week high at $14.12

Alpha Tau Medical shares surged to a 52-week high of $14.12 on Friday, marking the company’s strongest valuation since mid-2023. The milestone comes as the biotechnology sector continues to benefit from renewed investor interest in early-stage oncology and immunotherapy developers.

The stock’s latest advance follows a period of volatility, with shares trading well below prior peaks earlier this year. The company, which focuses on targeted alpha radiation therapy for solid tumors, has seen its valuation fluctuate alongside clinical trial updates and broader market sentiment toward high-risk, high-reward biotech plays.

Alpha Tau has not provided an official statement regarding the price movement. Trading volumes were elevated compared with the 30-day average, suggesting heightened retail and institutional interest in the name. The stock remains a speculative bet given its limited revenue and reliance on clinical progress.

The broader biotech index, as tracked by the SPDR S&P Biotech ETF, has gained roughly 15% over the past three months, outpacing the S&P 500’s advance. Analysts attribute the sector’s rebound to improved liquidity conditions, reduced regulatory uncertainty, and a pickup in merger and acquisition activity among mid-cap biotech firms.